ID   DNM3B_HUMAN             Reviewed;         853 AA.
AC   Q9UBC3; A2A2E2; B4DSM8; B4DSU1; E1P5M6; E1P5M7; E7EN63; E9PBF2;
AC   Q9UBD4; Q9UJQ5; Q9UKA6; Q9UNE5; Q9Y5R9; Q9Y5S0;
DT   26-SEP-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   10-MAY-2017, entry version 174.
DE   RecName: Full=DNA (cytosine-5)-methyltransferase 3B;
DE            Short=Dnmt3b;
DE            EC=2.1.1.37;
DE   AltName: Full=DNA methyltransferase HsaIIIB;
DE            Short=DNA MTase HsaIIIB;
DE            Short=M.HsaIIIB;
GN   Name=DNMT3B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Fetal testis, and Small intestine;
RX   PubMed=10433969; DOI=10.1016/S0378-1119(99)00252-8;
RA   Xie S., Wang Z., Okano M., Nogami M., Li Y., He W.-W., Okumura K.,
RA   Li E.;
RT   "Cloning, expression and chromosome locations of the human DNMT3 gene
RT   family.";
RL   Gene 236:87-95(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 6), AND VARIANTS ICF1 SER-663;
RP   GLY-726; GLY-817 AND MET-818.
RC   TISSUE=Testis;
RX   PubMed=10647011; DOI=10.1038/46052;
RA   Xu G.-L., Bestor T.H., Bourc'his D., Hsieh C.-L., Tommerup N.,
RA   Bugge M., Hulten M., Qu X., Russo J.J., Viegas-Pequignot E.;
RT   "Chromosome instability and immunodeficiency syndrome caused by
RT   mutations in a DNA methyltransferase gene.";
RL   Nature 402:187-191(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Ni J., Pradhan S., Roberts R.J.;
RT   "Cloning, expression and characterization of human DNMT3 genes.";
RL   Submitted (DEC-2000) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 7 AND 8).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 636-853 (ISOFORMS 1; 4 AND 5).
RC   TISSUE=Testis;
RX   PubMed=10325416; DOI=10.1093/nar/27.11.2291;
RA   Robertson K.D., Uzvolgyi E., Liang G., Talmadge C., Sumegi J.,
RA   Gonzales F.A., Jones P.A.;
RT   "The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate
RT   mRNA expression in normal tissues and overexpression in tumors.";
RL   Nucleic Acids Res. 27:2291-2298(1999).
RN   [8]
RP   INTERACTION WITH UBL1 AND UBE2I9, SUMOYLATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=11735126; DOI=10.1006/bbrc.2001.6057;
RA   Kang E.S., Park C.W., Chung J.H.;
RT   "Dnmt3b, de novo DNA methyltransferase, interacts with SUMO-1 and Ubc9
RT   through its N-terminal region and is subject to modification by SUMO-
RT   1.";
RL   Biochem. Biophys. Res. Commun. 289:862-868(2001).
RN   [9]
RP   INTERACTION WITH DNMT1 AND DNMT3A, AND SUBCELLULAR LOCATION.
RX   PubMed=12145218; DOI=10.1093/emboj/cdf401;
RA   Kim G.-D., Ni J., Kelesoglu N., Roberts R.J., Pradhan S.;
RT   "Co-operation and communication between the human maintenance and de
RT   novo DNA (cytosine-5) methyltransferases.";
RL   EMBO J. 21:4183-4195(2002).
RN   [10]
RP   INTERACTION WITH SETDB1.
RX   PubMed=16682412; DOI=10.1074/jbc.M513249200;
RA   Li H., Rauch T., Chen Z.-X., Szabo P.E., Riggs A.D., Pfeifer G.P.;
RT   "The histone methyltransferase SETDB1 and the DNA methyltransferase
RT   DNMT3A interact directly and localize to promoters silenced in cancer
RT   cells.";
RL   J. Biol. Chem. 281:19489-19500(2006).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH THE PRC2/EED-EZH2 COMPLEX.
RX   PubMed=16357870; DOI=10.1038/nature04431;
RA   Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C.,
RA   Morey L., Van Eynde A., Bernard D., Vanderwinden J.-M., Bollen M.,
RA   Esteller M., Di Croce L., de Launoit Y., Fuks F.;
RT   "The Polycomb group protein EZH2 directly controls DNA methylation.";
RL   Nature 439:871-874(2006).
RN   [12]
RP   ERRATUM.
RA   Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C.,
RA   Morey L., Van Eynde A., Bernard D., Vanderwinden J.-M., Bollen M.,
RA   Esteller M., Di Croce L., de Launoit Y., Fuks F.;
RL   Nature 446:824-824(2006).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH ZHX1.
RX   PubMed=17303076; DOI=10.1016/j.bbrc.2007.01.187;
RA   Kim S.H., Park J., Choi M.C., Kim H.P., Park J.H., Jung Y., Lee J.H.,
RA   Oh D.Y., Im S.A., Bang Y.J., Kim T.Y.;
RT   "Zinc-fingers and homeoboxes 1 (ZHX1) binds DNA methyltransferase
RT   (DNMT) 3B to enhance DNMT3B-mediated transcriptional repression.";
RL   Biochem. Biophys. Res. Commun. 355:318-323(2007).
RN   [14]
RP   DE NOVO DNA METHYLATION OF TARGET GENES.
RX   PubMed=17200670; DOI=10.1038/ng1950;
RA   Schlesinger Y., Straussman R., Keshet I., Farkash S., Hecht M.,
RA   Zimmerman J., Eden E., Yakhini Z., Ben-Shushan E., Reubinoff B.E.,
RA   Bergman Y., Simon I., Cedar H.;
RT   "Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes
RT   for de novo methylation in cancer.";
RL   Nat. Genet. 39:232-236(2007).
RN   [15]
RP   FUNCTION.
RX   PubMed=18413740; DOI=10.1158/0008-5472.CAN-07-6654;
RA   Sun L., Huang L., Nguyen P., Bisht K.S., Bar-Sela G., Ho A.S.,
RA   Bradbury C.M., Yu W., Cui H., Lee S., Trepel J.B., Feinberg A.P.,
RA   Gius D.;
RT   "DNA methyltransferase 1 and 3B activate BAG-1 expression via
RT   recruitment of CTCFL/BORIS and modulation of promoter histone
RT   methylation.";
RL   Cancer Res. 68:2726-2735(2008).
RN   [16]
RP   FUNCTION.
RX   PubMed=18567530; DOI=10.1016/j.biocel.2008.04.018;
RA   Kim S.-H., Park J., Choi M.-C., Park J.-H., Kim H.-P., Lee J.-H.,
RA   Oh D.-Y., Im S.-A., Bang Y.-J., Kim T.-Y.;
RT   "DNA methyltransferase 3B acts as a co-repressor of the human polycomb
RT   protein hPc2 to repress fibroblast growth factor receptor 3
RT   transcription.";
RL   Int. J. Biochem. Cell Biol. 40:2462-2471(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-136, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-82; THR-96; SER-100;
RP   SER-110; SER-136; SER-195; SER-202 AND SER-209, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-136 AND SER-209, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 206-355.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of the PWWP domain of human DNA (cytosine-5-)-
RT   methyltransferase 3 beta.";
RL   Submitted (MAR-2009) to the PDB data bank.
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.04 ANGSTROMS) OF 380-509.
RX   PubMed=21720545; DOI=10.1371/journal.pone.0018919;
RA   Wu H., Zeng H., Lam R., Tempel W., Amaya M.F., Xu C., Dombrovski L.,
RA   Qiu W., Wang Y., Min J.;
RT   "Structural and histone binding ability characterizations of human
RT   PWWP domains.";
RL   PLoS ONE 6:E18919-E18919(2011).
RN   [22]
RP   VARIANTS ICF1 THR-603 AND SER-THR-PRO-806 INS.
RX   PubMed=10555141; DOI=10.1016/S0092-8674(00)81656-6;
RA   Okano M., Bell D.W., Haber D.A., Li E.;
RT   "DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo
RT   methylation and mammalian development.";
RL   Cell 99:247-257(1999).
RN   [23]
RP   VARIANTS ICF1 THR-603; GLY-726 AND SER-THR-PRO-806 INS.
RX   PubMed=10588719; DOI=10.1073/pnas.96.25.14412;
RA   Hansen R.S., Wijmenga C., Luo P., Stanek A.M., Canfield T.K.,
RA   Weemaes C.M.R., Gartler S.M.;
RT   "The DNMT3B DNA methyltransferase gene is mutated in the ICF
RT   immunodeficiency syndrome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:14412-14417(1999).
RN   [24]
RP   VARIANTS ICF1 VAL-585; THR-603; ALA-606; GLY-699; GLY-726; PRO-766;
RP   ARG-814 AND MET-818.
RX   PubMed=11102980;
RX   DOI=10.1002/1098-1004(200012)16:6<509::AID-HUMU8>3.0.CO;2-V;
RA   Wijmenga C., Hansen R.S., Gimelli G., Bjoerck E.J., Davies E.G.,
RA   Valentine D., Belohradsky B.H., van Dongen J.J., Smeets D.F.C.M.,
RA   van den Heuvel L.P.W.J., Luyten J.A.F.M., Strengman E.,
RA   Weemaes C.M.R., Pearson P.L.;
RT   "Genetic variation in ICF syndrome: evidence for genetic
RT   heterogeneity.";
RL   Hum. Mutat. 16:509-517(2000).
RN   [25]
RP   VARIANTS ICF1 PRO-270; VAL-585; THR-603; ALA-606; SER-663; PRO-664;
RP   GLY-699; GLY-726; PRO-766; ARG-814; GLY-817; MET-818 AND GLN-840.
RX   PubMed=15580563; DOI=10.1002/humu.20113;
RA   Jiang Y.L., Rigolet M., Bourc'his D., Nigon F., Bokesoy I.,
RA   Fryns J.-P., Hulten M., Jonveaux P., Maraschio P., Megarbane A.,
RA   Moncla A., Viegas-Pequignot E.;
RT   "DNMT3B mutations and DNA methylation defect define two types of ICF
RT   syndrome.";
RL   Hum. Mutat. 25:56-63(2005).
RN   [26]
RP   VARIANT ICF1 MET-836.
RX   PubMed=21120685; DOI=10.1007/s10875-010-9488-0;
RA   Kaya N., Al-Muhsen S., Al-Saud B., Al-Bakheet A., Colak D.,
RA   Al-Ghonaium A., Al-Dhekri H., Al-Mousa H., Arnaout R., Al-Owain M.,
RA   Iqbal M.;
RT   "ICF syndrome in Saudi Arabia: immunological, cytogenetic and
RT   molecular analysis.";
RL   J. Clin. Immunol. 31:245-252(2011).
RN   [27]
RP   VARIANTS FSHD2 ARG-527 AND LEU-691, AND FUNCTION.
RX   PubMed=27153398; DOI=10.1016/j.ajhg.2016.03.013;
RA   van den Boogaard M.L., Lemmers R.J., Balog J., Wohlgemuth M.,
RA   Auranen M., Mitsuhashi S., van der Vliet P.J., Straasheijm K.R.,
RA   van den Akker R.F., Kriek M., Laurense-Bik M.E., Raz V.,
RA   van Ostaijen-Ten Dam M.M., Hansson K.B., van der Kooi E.L.,
RA   Kiuru-Enari S., Udd B., van Tol M.J., Nishino I., Tawil R.,
RA   Tapscott S.J., van Engelen B.G., van der Maarel S.M.;
RT   "Mutations in DNMT3B modify epigenetic repression of the D4Z4 repeat
RT   and the penetrance of facioscapulohumeral dystrophy.";
RL   Am. J. Hum. Genet. 98:1020-1029(2016).
RN   [28]
RP   VARIANT ICF1 THR-585.
RX   PubMed=27734333; DOI=10.1007/s10875-016-0340-z;
RA   Rechavi E., Lev A., Eyal E., Barel O., Kol N., Barhom S.F.,
RA   Pode-Shakked B., Anikster Y., Somech R., Simon A.J.;
RT   "A novel mutation in a critical region for the methyl donor binding in
RT   DNMT3B causes immunodeficiency, centromeric instability, and facial
RT   anomalies syndrome (ICF).";
RL   J. Clin. Immunol. 36:801-809(2016).
CC   -!- FUNCTION: Required for genome-wide de novo methylation and is
CC       essential for the establishment of DNA methylation patterns during
CC       development. DNA methylation is coordinated with methylation of
CC       histones. May preferentially methylates nucleosomal DNA within the
CC       nucleosome core region. May function as transcriptional co-
CC       repressor by associating with CBX4 and independently of DNA
CC       methylation. Seems to be involved in gene silencing (By
CC       similarity). In association with DNMT1 and via the recruitment of
CC       CTCFL/BORIS, involved in activation of BAG1 gene expression by
CC       modulating dimethylation of promoter histone H3 at H3K4 and H3K9.
CC       Isoforms 4 and 5 are probably not functional due to the deletion
CC       of two conserved methyltransferase motifs. Function as
CC       transcriptional corepressor by associating with ZHX1. Required for
CC       DUX4 silencing in somatic cells (PubMed:27153398). {ECO:0000250,
CC       ECO:0000269|PubMed:16357870, ECO:0000269|PubMed:17303076,
CC       ECO:0000269|PubMed:18413740, ECO:0000269|PubMed:18567530,
CC       ECO:0000269|PubMed:27153398}.
CC   -!- CATALYTIC ACTIVITY: S-adenosyl-L-methionine + DNA = S-adenosyl-L-
CC       homocysteine + DNA containing 5-methylcytosine.
CC       {ECO:0000255|PROSITE-ProRule:PRU10018}.
CC   -!- ENZYME REGULATION: Activated by binding to the regulatory factor
CC       DNMT3L. {ECO:0000250}.
CC   -!- SUBUNIT: Interacts with BAZ2A/TIP5, SUV39H1 and CBX4. Interacts
CC       with UHRF1 (By similarity). Interacts with DNMT1 and DNMT3A,
CC       SETDB1, UBL1, UBE2I9 and ZHX1. Interacts with the PRC2/EED-EZH2
CC       complex. {ECO:0000250, ECO:0000269|PubMed:11735126,
CC       ECO:0000269|PubMed:12145218, ECO:0000269|PubMed:16357870,
CC       ECO:0000269|PubMed:16682412, ECO:0000269|PubMed:17303076}.
CC   -!- INTERACTION:
CC       O75530:EED; NbExp=4; IntAct=EBI-80125, EBI-923794;
CC       Q15910:EZH2; NbExp=14; IntAct=EBI-80125, EBI-530054;
CC       P63165:SUMO1; NbExp=4; IntAct=EBI-80125, EBI-80140;
CC       P63279:UBE2I; NbExp=3; IntAct=EBI-80125, EBI-80168;
CC       Q96T88:UHRF1; NbExp=7; IntAct=EBI-80125, EBI-1548946;
CC       Q9UKY1:ZHX1; NbExp=6; IntAct=EBI-6083193, EBI-347767;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11735126,
CC       ECO:0000269|PubMed:12145218}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=8;
CC       Name=1;
CC         IsoId=Q9UBC3-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9UBC3-2; Sequence=VSP_005637;
CC       Name=3;
CC         IsoId=Q9UBC3-3; Sequence=VSP_005637, VSP_005638;
CC       Name=4;
CC         IsoId=Q9UBC3-4; Sequence=VSP_005637, VSP_005639, VSP_005640;
CC       Name=5;
CC         IsoId=Q9UBC3-5; Sequence=VSP_005637, VSP_005641;
CC       Name=6;
CC         IsoId=Q9UBC3-6; Sequence=VSP_005636, VSP_005637;
CC       Name=7;
CC         IsoId=Q9UBC3-7; Sequence=VSP_045874, VSP_005637, VSP_045876;
CC         Note=No experimental confirmation available.;
CC       Name=8;
CC         IsoId=Q9UBC3-8; Sequence=VSP_045875, VSP_005637, VSP_045876;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Ubiquitous; highly expressed in fetal liver,
CC       heart, kidney, placenta, and at lower levels in spleen, colon,
CC       brain, liver, small intestine, lung, peripheral blood mononuclear
CC       cells, and skeletal muscle. Isoform 1 is expressed in all tissues
CC       except brain, skeletal muscle and PBMC, 3 is ubiquitous, 4 is
CC       expressed in all tissues except brain, skeletal muscle, lung and
CC       prostate and 5 is detectable only in testis and at very low level
CC       in brain and prostate.
CC   -!- DOMAIN: The PWWP domain is essential for targeting to pericentric
CC       heterochromatin.
CC   -!- PTM: Sumoylated. {ECO:0000269|PubMed:11735126}.
CC   -!- PTM: Citrullinated by PADI4. {ECO:0000250}.
CC   -!- DISEASE: Immunodeficiency-centromeric instability-facial anomalies
CC       syndrome 1 (ICF1) [MIM:242860]: A rare disorder characterized by a
CC       variable immunodeficiency resulting in recurrent infections,
CC       facial anomalies, and branching of chromosomes 1, 9, and 16. Other
CC       variable symptoms include growth retardation, failure to thrive,
CC       and psychomotor retardation. Laboratory studies show limited
CC       hypomethylation of DNA in a small fraction of the genome in some,
CC       but not all, patients. {ECO:0000269|PubMed:10555141,
CC       ECO:0000269|PubMed:10588719, ECO:0000269|PubMed:10647011,
CC       ECO:0000269|PubMed:11102980, ECO:0000269|PubMed:15580563,
CC       ECO:0000269|PubMed:21120685, ECO:0000269|PubMed:27734333}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Facioscapulohumeral muscular dystrophy 2 (FSHD2)
CC       [MIM:158901]: A degenerative muscle disease characterized by
CC       slowly progressive weakness of the muscles of the face, upper-arm,
CC       and shoulder girdle. The onset of symptoms usually occurs in the
CC       first or second decade of life. Affected individuals usually
CC       present with impairment of upper extremity elevation. This tends
CC       to be followed by facial weakness, primarily involving the
CC       orbicularis oris and orbicularis oculi muscles.
CC       {ECO:0000269|PubMed:27153398}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry. DNMT3B
CC       mutations lead to DUX4 expression in somatic tissues, including
CC       muscle cells, when an haplotype on chromosome 4 is permissive for
CC       DUX4 expression. Ectopic expression of DUX4 in skeletal muscle
CC       activates the expression of stem cell and germline genes, and,
CC       when overexpressed in somatic cells, DUX4 can ultimately lead to
CC       cell death.
CC   -!- SIMILARITY: Belongs to the class I-like SAM-binding
CC       methyltransferase superfamily. C5-methyltransferase family.
CC       {ECO:0000255|PROSITE-ProRule:PRU01016}.
CC   -!- WEB RESOURCE: Name=DNMT3Bbase; Note=DNMT3B mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/DNMT3Bbase/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF156487; AAD53062.1; -; mRNA.
DR   EMBL; AF156488; AAD53063.1; -; mRNA.
DR   EMBL; AF176228; AAF04015.1; -; mRNA.
DR   EMBL; AF331857; AAL57040.1; -; mRNA.
DR   EMBL; AK299821; BAG61690.1; -; mRNA.
DR   EMBL; AK299915; BAG61753.1; -; mRNA.
DR   EMBL; AL035071; CAB53069.1; -; Genomic_DNA.
DR   EMBL; AL035071; CAB53070.1; -; Genomic_DNA.
DR   EMBL; AL035071; CAB53071.1; -; Genomic_DNA.
DR   EMBL; AL035071; CAM27373.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW76351.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW76352.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW76353.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW76354.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW76356.1; -; Genomic_DNA.
DR   EMBL; AF129267; AAD31432.1; -; mRNA.
DR   EMBL; AF129268; AAD31433.1; -; mRNA.
DR   EMBL; AF129269; AAD31434.1; -; mRNA.
DR   CCDS; CCDS13204.1; -. [Q9UBC3-6]
DR   CCDS; CCDS13205.1; -. [Q9UBC3-1]
DR   CCDS; CCDS13206.1; -. [Q9UBC3-2]
DR   CCDS; CCDS13207.1; -. [Q9UBC3-3]
DR   CCDS; CCDS56183.1; -. [Q9UBC3-8]
DR   CCDS; CCDS56184.1; -. [Q9UBC3-7]
DR   RefSeq; NP_001193984.1; NM_001207055.1. [Q9UBC3-8]
DR   RefSeq; NP_001193985.1; NM_001207056.1. [Q9UBC3-7]
DR   RefSeq; NP_008823.1; NM_006892.3. [Q9UBC3-1]
DR   RefSeq; NP_787044.1; NM_175848.1. [Q9UBC3-2]
DR   RefSeq; NP_787045.1; NM_175849.1. [Q9UBC3-3]
DR   RefSeq; NP_787046.1; NM_175850.2. [Q9UBC3-6]
DR   UniGene; Hs.643024; -.
DR   UniGene; Hs.713611; -.
DR   PDB; 3FLG; X-ray; 1.80 A; A=206-355.
DR   PDB; 3QKJ; X-ray; 2.04 A; A/B/C/D=206-355.
DR   PDB; 5CIU; X-ray; 2.24 A; A/B=206-355.
DR   PDBsum; 3FLG; -.
DR   PDBsum; 3QKJ; -.
DR   PDBsum; 5CIU; -.
DR   ProteinModelPortal; Q9UBC3; -.
DR   SMR; Q9UBC3; -.
DR   BioGrid; 108126; 70.
DR   DIP; DIP-30000N; -.
DR   IntAct; Q9UBC3; 27.
DR   MINT; MINT-2820816; -.
DR   STRING; 9606.ENSP00000328547; -.
DR   BindingDB; Q9UBC3; -.
DR   ChEMBL; CHEMBL6095; -.
DR   REBASE; 4120; M.HsaDnmt3B.
DR   iPTMnet; Q9UBC3; -.
DR   PhosphoSitePlus; Q9UBC3; -.
DR   BioMuta; DNMT3B; -.
DR   DMDM; 17375667; -.
DR   EPD; Q9UBC3; -.
DR   MaxQB; Q9UBC3; -.
DR   PaxDb; Q9UBC3; -.
DR   PeptideAtlas; Q9UBC3; -.
DR   PRIDE; Q9UBC3; -.
DR   DNASU; 1789; -.
DR   Ensembl; ENST00000201963; ENSP00000201963; ENSG00000088305. [Q9UBC3-6]
DR   Ensembl; ENST00000328111; ENSP00000328547; ENSG00000088305. [Q9UBC3-1]
DR   Ensembl; ENST00000348286; ENSP00000337764; ENSG00000088305. [Q9UBC3-3]
DR   Ensembl; ENST00000353855; ENSP00000313397; ENSG00000088305. [Q9UBC3-2]
DR   Ensembl; ENST00000443239; ENSP00000403169; ENSG00000088305. [Q9UBC3-8]
DR   Ensembl; ENST00000456297; ENSP00000412305; ENSG00000088305. [Q9UBC3-7]
DR   GeneID; 1789; -.
DR   KEGG; hsa:1789; -.
DR   UCSC; uc002wyc.3; human. [Q9UBC3-1]
DR   CTD; 1789; -.
DR   DisGeNET; 1789; -.
DR   GeneCards; DNMT3B; -.
DR   HGNC; HGNC:2979; DNMT3B.
DR   HPA; CAB069896; -.
DR   HPA; HPA001595; -.
DR   MalaCards; DNMT3B; -.
DR   MIM; 158901; phenotype.
DR   MIM; 242860; phenotype.
DR   MIM; 602900; gene.
DR   neXtProt; NX_Q9UBC3; -.
DR   OpenTargets; ENSG00000088305; -.
DR   Orphanet; 2268; ICF syndrome.
DR   PharmGKB; PA27446; -.
DR   eggNOG; ENOG410IGHW; Eukaryota.
DR   eggNOG; ENOG410XQ4Y; LUCA.
DR   GeneTree; ENSGT00390000008341; -.
DR   HOGENOM; HOG000230875; -.
DR   HOVERGEN; HBG051381; -.
DR   InParanoid; Q9UBC3; -.
DR   KO; K17399; -.
DR   OMA; TRHLNGE; -.
DR   OrthoDB; EOG091G01TP; -.
DR   PhylomeDB; Q9UBC3; -.
DR   TreeFam; TF329039; -.
DR   BRENDA; 2.1.1.37; 2681.
DR   Reactome; R-HSA-212300; PRC2 methylates histones and DNA.
DR   Reactome; R-HSA-427413; NoRC negatively regulates rRNA expression.
DR   Reactome; R-HSA-5334118; DNA methylation.
DR   SIGNOR; Q9UBC3; -.
DR   ChiTaRS; DNMT3B; human.
DR   EvolutionaryTrace; Q9UBC3; -.
DR   GeneWiki; DNMT3B; -.
DR   GenomeRNAi; 1789; -.
DR   PRO; PR:Q9UBC3; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   Bgee; ENSG00000088305; -.
DR   CleanEx; HS_DNMT3B; -.
DR   Genevisible; Q9UBC3; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IEA:Ensembl.
DR   GO; GO:0003886; F:DNA (cytosine-5-)-methyltransferase activity; IDA:MGI.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0009008; F:DNA-methyltransferase activity; TAS:Reactome.
DR   GO; GO:0042826; F:histone deacetylase binding; IEA:Ensembl.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003714; F:transcription corepressor activity; IDA:UniProtKB.
DR   GO; GO:0071549; P:cellular response to dexamethasone stimulus; IEA:Ensembl.
DR   GO; GO:0071455; P:cellular response to hyperoxia; IEA:Ensembl.
DR   GO; GO:0006306; P:DNA methylation; TAS:UniProtKB.
DR   GO; GO:0045814; P:negative regulation of gene expression, epigenetic; TAS:Reactome.
DR   GO; GO:0051573; P:negative regulation of histone H3-K9 methylation; IMP:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0051571; P:positive regulation of histone H3-K4 methylation; IMP:UniProtKB.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0031000; P:response to caffeine; IEA:Ensembl.
DR   GO; GO:0042220; P:response to cocaine; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0010212; P:response to ionizing radiation; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:0033189; P:response to vitamin A; IEA:Ensembl.
DR   CDD; cd11728; ADDz_Dnmt3b; 1.
DR   InterPro; IPR025766; ADD.
DR   InterPro; IPR018117; C5_DNA_meth_AS.
DR   InterPro; IPR001525; C5_MeTfrase.
DR   InterPro; IPR030488; DNMT3B_ADD.
DR   InterPro; IPR000313; PWWP_dom.
DR   InterPro; IPR029063; SAM-dependent_MTases.
DR   InterPro; IPR011011; Znf_FYVE_PHD.
DR   Pfam; PF00145; DNA_methylase; 1.
DR   Pfam; PF00855; PWWP; 1.
DR   SMART; SM00293; PWWP; 1.
DR   SUPFAM; SSF53335; SSF53335; 1.
DR   SUPFAM; SSF57903; SSF57903; 1.
DR   PROSITE; PS51533; ADD; 1.
DR   PROSITE; PS00094; C5_MTASE_1; 1.
DR   PROSITE; PS50812; PWWP; 1.
DR   PROSITE; PS51679; SAM_MT_C5; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Citrullination;
KW   Complete proteome; Disease mutation; DNA-binding; Metal-binding;
KW   Methyltransferase; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repressor; S-adenosyl-L-methionine; Transferase;
KW   Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN         1    853       DNA (cytosine-5)-methyltransferase 3B.
FT                                /FTId=PRO_0000088045.
FT   DOMAIN      225    283       PWWP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00162}.
FT   DOMAIN      423    555       ADD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00865}.
FT   DOMAIN      575    853       SAM-dependent MTase C5-type.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01016}.
FT   ZN_FING     434    464       GATA-type; atypical.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00865}.
FT   ZN_FING     475    531       PHD-type; atypical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00865}.
FT   REGION        1    298       Interaction with DNMT1 and DNMT3A.
FT                                {ECO:0000269|PubMed:12145218}.
FT   REGION      435    527       Interaction with the PRC2/EED-EZH2
FT                                complex. {ECO:0000250}.
FT   REGION      582    586       S-adenosyl-L-homocysteine binding.
FT                                {ECO:0000250|UniProtKB:Q9Y6K1}.
FT   REGION      627    629       S-adenosyl-L-homocysteine binding.
FT                                {ECO:0000250|UniProtKB:Q9Y6K1}.
FT   REGION      832    834       S-adenosyl-L-homocysteine binding.
FT                                {ECO:0000250|UniProtKB:Q9Y6K1}.
FT   ACT_SITE    651    651       {ECO:0000255|PROSITE-ProRule:PRU01016,
FT                                ECO:0000255|PROSITE-ProRule:PRU10018}.
FT   BINDING     605    605       S-adenosyl-L-homocysteine.
FT                                {ECO:0000250|UniProtKB:Q9Y6K1}.
FT   MOD_RES      82     82       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES      96     96       Phosphothreonine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES     100    100       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES     110    110       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES     136    136       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     195    195       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES     202    202       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES     209    209       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     410    410       Citrulline. {ECO:0000250}.
FT   VAR_SEQ       1      1       M -> MEPSPEPPSLESM (in isoform 6).
FT                                {ECO:0000303|PubMed:10647011}.
FT                                /FTId=VSP_005636.
FT   VAR_SEQ      69    144       Missing (in isoform 7).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_045874.
FT   VAR_SEQ     103    144       Missing (in isoform 8).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_045875.
FT   VAR_SEQ     356    375       Missing (in isoform 2, isoform 3, isoform
FT                                4, isoform 5, isoform 6, isoform 7 and
FT                                isoform 8). {ECO:0000303|PubMed:10325416,
FT                                ECO:0000303|PubMed:10433969,
FT                                ECO:0000303|PubMed:10647011,
FT                                ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_005637.
FT   VAR_SEQ     744    806       Missing (in isoform 7 and isoform 8).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_045876.
FT   VAR_SEQ     744    744       R -> S (in isoform 4).
FT                                {ECO:0000303|PubMed:10325416}.
FT                                /FTId=VSP_005639.
FT   VAR_SEQ     745    853       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:10325416}.
FT                                /FTId=VSP_005640.
FT   VAR_SEQ     745    807       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:10433969}.
FT                                /FTId=VSP_005638.
FT   VAR_SEQ     768    853       LKKVQTITTKSNSIKQGKNQLFPVVMNGKEDVLWCTELERI
FT                                FGFPVHYTDVSNMGRGARQKLLGRSWSVPVIRHLFAPLKDY
FT                                FACE -> DLWLSCALHRRVQHGPWCPPEAAGKVLERACHP
FT                                TPLRPSEGLLCM (in isoform 5).
FT                                {ECO:0000303|PubMed:10325416}.
FT                                /FTId=VSP_005641.
FT   VARIANT      54     54       R -> P (in dbSNP:rs17123590).
FT                                /FTId=VAR_033885.
FT   VARIANT     270    270       S -> P (in ICF1; dbSNP:rs121908947).
FT                                {ECO:0000269|PubMed:15580563}.
FT                                /FTId=VAR_022579.
FT   VARIANT     527    527       C -> R (in FSHD2).
FT                                {ECO:0000269|PubMed:27153398}.
FT                                /FTId=VAR_077527.
FT   VARIANT     585    585       A -> T (in ICF1; dbSNP:rs750849178).
FT                                {ECO:0000269|PubMed:27734333}.
FT                                /FTId=VAR_077528.
FT   VARIANT     585    585       A -> V (in ICF1).
FT                                {ECO:0000269|PubMed:11102980,
FT                                ECO:0000269|PubMed:15580563}.
FT                                /FTId=VAR_011506.
FT   VARIANT     603    603       A -> T (in ICF1; dbSNP:rs121908943).
FT                                {ECO:0000269|PubMed:10555141,
FT                                ECO:0000269|PubMed:10588719,
FT                                ECO:0000269|PubMed:11102980,
FT                                ECO:0000269|PubMed:15580563}.
FT                                /FTId=VAR_011499.
FT   VARIANT     606    606       V -> A (in ICF1; dbSNP:rs146981624).
FT                                {ECO:0000269|PubMed:11102980,
FT                                ECO:0000269|PubMed:15580563}.
FT                                /FTId=VAR_011507.
FT   VARIANT     663    663       G -> S (in ICF1; dbSNP:rs121908942).
FT                                {ECO:0000269|PubMed:10647011,
FT                                ECO:0000269|PubMed:15580563}.
FT                                /FTId=VAR_011500.
FT   VARIANT     664    664       L -> P (in ICF1).
FT                                {ECO:0000269|PubMed:15580563}.
FT                                /FTId=VAR_022580.
FT   VARIANT     691    691       P -> L (in FSHD2).
FT                                {ECO:0000269|PubMed:27153398}.
FT                                /FTId=VAR_077529.
FT   VARIANT     699    699       V -> G (in ICF1).
FT                                {ECO:0000269|PubMed:11102980,
FT                                ECO:0000269|PubMed:15580563}.
FT                                /FTId=VAR_011508.
FT   VARIANT     726    726       V -> G (in ICF1; dbSNP:rs121908941).
FT                                {ECO:0000269|PubMed:10588719,
FT                                ECO:0000269|PubMed:10647011,
FT                                ECO:0000269|PubMed:11102980,
FT                                ECO:0000269|PubMed:15580563}.
FT                                /FTId=VAR_011501.
FT   VARIANT     766    766       A -> P (in ICF1).
FT                                {ECO:0000269|PubMed:11102980,
FT                                ECO:0000269|PubMed:15580563}.
FT                                /FTId=VAR_011509.
FT   VARIANT     806    806       E -> ESTP (in ICF1).
FT                                /FTId=VAR_011502.
FT   VARIANT     814    814       H -> R (in ICF1).
FT                                {ECO:0000269|PubMed:11102980,
FT                                ECO:0000269|PubMed:15580563}.
FT                                /FTId=VAR_011510.
FT   VARIANT     817    817       D -> G (in ICF1; dbSNP:rs121908939).
FT                                {ECO:0000269|PubMed:10647011,
FT                                ECO:0000269|PubMed:15580563}.
FT                                /FTId=VAR_011503.
FT   VARIANT     818    818       V -> M (in ICF1; dbSNP:rs121908940).
FT                                {ECO:0000269|PubMed:10647011,
FT                                ECO:0000269|PubMed:11102980,
FT                                ECO:0000269|PubMed:15580563}.
FT                                /FTId=VAR_011504.
FT   VARIANT     836    836       V -> M (in ICF1; unknown pathological
FT                                significance; dbSNP:rs866792483).
FT                                {ECO:0000269|PubMed:21120685}.
FT                                /FTId=VAR_077530.
FT   VARIANT     840    840       R -> Q (in ICF1; dbSNP:rs121908946).
FT                                {ECO:0000269|PubMed:15580563}.
FT                                /FTId=VAR_022581.
FT   CONFLICT    575    575       I -> T (in Ref. 4; BAG61690).
FT                                {ECO:0000305}.
FT   CONFLICT    583    583       G -> D (in Ref. 4; BAG61753).
FT                                {ECO:0000305}.
FT   CONFLICT    655    655       S -> P (in Ref. 4; BAG61690).
FT                                {ECO:0000305}.
FT   STRAND      219    222       {ECO:0000244|PDB:5CIU}.
FT   STRAND      228    231       {ECO:0000244|PDB:3FLG}.
FT   STRAND      239    244       {ECO:0000244|PDB:3FLG}.
FT   HELIX       246    249       {ECO:0000244|PDB:3FLG}.
FT   STRAND      258    263       {ECO:0000244|PDB:3FLG}.
FT   TURN        264    266       {ECO:0000244|PDB:3FLG}.
FT   STRAND      269    273       {ECO:0000244|PDB:3FLG}.
FT   TURN        274    276       {ECO:0000244|PDB:3FLG}.
FT   STRAND      277    279       {ECO:0000244|PDB:3QKJ}.
FT   HELIX       283    286       {ECO:0000244|PDB:3FLG}.
FT   HELIX       289    294       {ECO:0000244|PDB:3FLG}.
FT   HELIX       296    313       {ECO:0000244|PDB:3FLG}.
FT   HELIX       325    337       {ECO:0000244|PDB:3FLG}.
FT   TURN        341    343       {ECO:0000244|PDB:3FLG}.
FT   HELIX       345    348       {ECO:0000244|PDB:3FLG}.
SQ   SEQUENCE   853 AA;  95751 MW;  F20A67CF78951532 CRC64;
     MKGDTRHLNG EEDAGGREDS ILVNGACSDQ SSDSPPILEA IRTPEIRGRR SSSRLSKREV
     SSLLSYTQDL TGDGDGEDGD GSDTPVMPKL FRETRTRSES PAVRTRNNNS VSSRERHRPS
     PRSTRGRQGR NHVDESPVEF PATRSLRRRA TASAGTPWPS PPSSYLTIDL TDDTEDTHGT
     PQSSSTPYAR LAQDSQQGGM ESPQVEADSG DGDSSEYQDG KEFGIGDLVW GKIKGFSWWP
     AMVVSWKATS KRQAMSGMRW VQWFGDGKFS EVSADKLVAL GLFSQHFNLA TFNKLVSYRK
     AMYHALEKAR VRAGKTFPSS PGDSLEDQLK PMLEWAHGGF KPTGIEGLKP NNTQPVVNKS
     KVRRAGSRKL ESRKYENKTR RRTADDSATS DYCPAPKRLK TNCYNNGKDR GDEDQSREQM
     ASDVANNKSS LEDGCLSCGR KNPVSFHPLF EGGLCQTCRD RFLELFYMYD DDGYQSYCTV
     CCEGRELLLC SNTSCCRCFC VECLEVLVGT GTAAEAKLQE PWSCYMCLPQ RCHGVLRRRK
     DWNVRLQAFF TSDTGLEYEA PKLYPAIPAA RRRPIRVLSL FDGIATGYLV LKELGIKVGK
     YVASEVCEES IAVGTVKHEG NIKYVNDVRN ITKKNIEEWG PFDLVIGGSP CNDLSNVNPA
     RKGLYEGTGR LFFEFYHLLN YSRPKEGDDR PFFWMFENVV AMKVGDKRDI SRFLECNPVM
     IDAIKVSAAH RARYFWGNLP GMNRPVIASK NDKLELQDCL EYNRIAKLKK VQTITTKSNS
     IKQGKNQLFP VVMNGKEDVL WCTELERIFG FPVHYTDVSN MGRGARQKLL GRSWSVPVIR
     HLFAPLKDYF ACE
//
